10272-06-7

Basic information

• Product Name: 3-chloro-5-methoxyaniline
• Synonyms: 3-chloro-5-methoxyaniline;Einecs 233-614-4;3-chloro-5-Methoxy-benzenaMine;3-Chloro-5-aminoanisole
• CAS NO: 10272-06-7
• Molecular Formula: C₇H₈ClNO
• Molecular Weight: 157.59752
• EINECS: 233-614-4
• Mol File: 10272-06-7.mol

Chemical Properties

• Melting Point: 33 °C
• Boiling Point: 280.3°Cat760mmHg
• Flash Point: 123.3°C
• Appearance: /
• Density: 1.234g/cm³
• Vapor Pressure: 0.00381mmHg at 25°C
• Refractive Index: 1.572
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 3.12±0.10(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: 3-chloro-5-methoxyaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-chloro-5-methoxyaniline(10272-06-7)
• EPA Substance Registry System: 3-chloro-5-methoxyaniline(10272-06-7)

Safety Data

• Hazardous Substances Data: 10272-06-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloro-5-methoxyaniline is used as a synthetic intermediate for the preparation of a range of pharmaceutical goods. Its unique chemical structure allows it to be a versatile building block in the development of new drugs, particularly those targeting specific biological pathways or receptors.
In the synthesis of pharmaceuticals, 3-chloro-5-methoxyaniline can be further modified or combined with other chemical entities to create active pharmaceutical ingredients (APIs) with desired therapeutic properties. Its presence in the final drug product may contribute to the drug's efficacy, safety, and pharmacokinetic profile, making it an important component in the drug discovery and development process.

InChI:InChI=1/C7H8ClNO/c1-10-7-3-5(8)2-6(9)4-7/h2-4H,9H2,1H3

Upstream product

• 33719-74-3 3,5-dichloroanisole 
• 99-65-0 meta-dinitrobenzene 
• 618-86-0 1-chloro-3,5-dinitrobenzene 
• 55910-07-1 1-chloro-3-methoxy-5-nitrobenzene 

Downstream Products

• 102236-20-4 3-chloro-5-methoxy-N,N-dimethyl-aniline 
• 65262-96-6 3-chloro-5-methoxyphenol 
• 174913-12-3 1-bromo-3-chloro-5-methoxybenzene 
• 861800-86-4 1-chloro-3-iodo-5-methoxybenzene 
• 855654-74-9 (3-chloro-5-methoxy-anilinomethylene)-malonic acid diethyl ester 
• 62606-11-5 (3-Chloro-5-methoxy-phenyl)-(2,4,6-trinitro-phenyl)-amine 
• 6324-16-9 7-chloro-4-hydroxy-5-methoxy-quinoline-3-carboxylic acid ethyl ester 
• 883195-40-2 3-amino-5-chlorophenol 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.

HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE

Provided are a heterocyclic carboxylic acid amide ligand and applications thereof in a copper catalyzed coupling reaction. Specifically, provided are uses of a compound represented by formula (I), definitions of radical groups being described in the specifications. The compound represented by formula (I) can be used as the ligand in the copper catalyzed coupling reaction of the aryl halogeno substitute, and is used or catalyzing the coupling reaction for forming the aryl halogeno substitute having C—N, C—O, C—S and other bonds.

Oxalic amide ligands, and uses thereof in copper-catalyzed coupling reaction of aryl halides

The present invention provides oxalic amide ligands and uses thereof in copper-catalyzed coupling reaction of aryl halides. Specifically, the present invention provides a use of a compound represented by formula I, wherein definitions of each group are described in the specification. The compound represented by formula I can be used as a ligand in copper-catalyzed coupling reaction of aryl halides for the formation of C—N, C—O and C—S bonds.

SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS

The present disclosure relates to compounds of Formula (I): (I) and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY

Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.

Assembly of Primary (Hetero)Arylamines via CuI/Oxalic Diamide-Catalyzed Coupling of Aryl Chlorides and Ammonia

A general and practical catalytic system for aryl amination of aryl chlorides with aqueous or gaseous ammonia has been developed, with CuI as the catalyst and bisaryl oxalic diamides as the ligands. The reaction proceeds at 105-120°C to provide a diverse set of primary (hetero)aryl amines in high yields with various functional groups.

NEW SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS

The present invention relates to substituted arylsulphonylglycines of general formula (I) wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof, which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1 ), and their use as pharmaceutical compositions.